

Supplementary Table: Supplement table with Adjusted Outcomes and sensitivity analysis

Outcome Variables	Unadjusted		Adjusted		Sens Analysis 1	P
	HR (95% CI)	P	HR (95% CI)	P	OR (95% CI)	
DISEASE SEVERITY PROGRESSION						
Severe Disease (IMV) or death*	1.28 (1.20 to 1.37)	<0.01	0.91 (0.84 to 0.99)	0.02	0.92 (0.85 to 0.99)	0.035
OUTCOME						
ICU admission	0.85 (0.80 to 0.91)	<0.01	0.78 (0.73 to 0.84)	<0.01	0.76 (0.71 to 0.82)	<0.01
Hospital mortality	1.48 (1.37 to 1.60)	<0.01	0.89 (0.82 to 0.97)	0.01	0.89 (0.81 to 0.97)	0.01
COMPLICATIONS						
CVA	1.40 (1.06 to 1.86)	0.02	1.07 (0.79 to 1.47)	0.65	1.07 (0.78 to 1.47)	0.66
GI hemorrhage	1.65 (1.25 to 2.18)	<0.01	1.14 (0.84 to 1.55)	0.40	1.16 (0.85 to 1.57)	0.34
Myocardial Infarction**	1.95 (1.70 to 2.25)	<0.01	1.21 (1.04 to 1.42)	0.02	1.23 (1.05 to 1.44)	0.01
Elevation in Troponin	1.93 (1.67 to 2.24)	<0.01	1.27 (1.09 to 1.50)	0.03	1.29 (1.11 to 1.52)	<0.01
ST elevation in EKG	2.56 (1.59 to 4.12)	<0.001	2.03 (1.18 to 3.47)	<0.01	2.09 (1.22 to 3.59)	<0.01
NEED FOR TRANSFUSION[¥]						
Any blood product transfusion (first 24 hr)	1.21 (0.98 to 1.51)	0.075	1.03 (0.82 to 1.30)	0.79	1.05 (0.83 to 1.33)	0.68
pRBC transfusion	1.29 (1.03 to 1.61)	0.028	1.07 (0.84 to 1.36)	0.59	1.09 (0.85 to 1.39)	0.50
LENGTH OF STAY MEASURES (Not HR but Days[95% CI])						
Hospital-free days	-1.14 (-1.46 to -0.81)	<0.01	1.00 (0.66 to 1.35)	<0.01	0.90	<0.001
ICU-free days	-2.19 (-2.76 to -1.63)	<0.01	0.33 (-0.27 to 0.93)	0.29	0.06	0.85
IMV-free days	0.50 (-0.13 to 1.13)	0.12	-0.27 (-0.96 to 0.40)	0.42	0.18	0.65

Adjusted models were adjusted for age, sex, ethnicity, race, and comorbidities of CAD, HTN, CHF, Stroke, chronic pulmonary diseases (COPD, asthma, pulmonary circulatory diseases), history of VTE, diabetes mellitus, chronic kidney disease and Obesity.

*WHO 6 or above, ** ST elevation in EKG or elevation in Troponin, [¥] (N = 11,654)

Sensitivity Analysis: Sensitivity Analysis: The model was the same as the original model PLUS additional adjustment for the time since the pandemic was divided into quarters (4 quarters in 2020 and 3 in 2021 for the data in this manuscript).